PRESS RELEASE published on 02/17/2024 at 01:50, 1 year 9 months ago BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
PRESS RELEASE published on 01/30/2024 at 05:48, 1 year 10 months ago BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
PRESS RELEASE published on 12/22/2023 at 09:05, 1 year 11 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/22/2023 at 01:50, 1 year 11 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/12/2023 at 09:05, 1 year 11 months ago BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
PRESS RELEASE published on 12/09/2023 at 04:30, 1 year 11 months ago BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
PRESS RELEASE published on 11/25/2023 at 01:44, 2 years ago Bionxt Solutions Announces Convertible Debenture and Interest Settlement
PRESS RELEASE published on 11/20/2023 at 09:05, 2 years ago BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
PRESS RELEASE published on 11/15/2023 at 09:05, 2 years ago BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
PRESS RELEASE published on 11/13/2023 at 09:05, 2 years ago BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Published on 12/05/2025 at 02:35, 7 hours 9 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 44 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 39 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 44 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:30, 14 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 39 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 59 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 44 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 15 hours 59 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
